Description
Obatoclax is a BH3 mimetic and inhibitor of Bcl-2 and Bcl-xl that displays anti-metastatic and anticancer chemotherapeutic activities; it is currently in clinical trials as a potential treatment for various cancers. Obatoclax induces autophagy and apoptosis in adenoid cystic carcinoma cells and decreases tumor formation and growth in animal models of hepatoblastoma. In cellular models of colorectal cancer, obatoclax inhibits cell growth, induces G1 phase cell cycle arrest, and suppresses proliferation, migration, and invasion.
References
Liang LZ, Ma B, Liang YJ, et al. Obatoclax induces Beclin 1- and ATG5-dependent apoptosis and autophagy in adenoid cystic carcinoma cells. Oral Dis. 2014 Dec 8. [Epub ahead of print]. PMID: 25482163.
Arellano ML, Borthakur G, Berger M, et al. A phase II, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopenia. Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):534-9. PMID: 25052051.
Koehler BC, Scherr AL, Lorenz S, et al. Pan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells. PLoS One. 2014 Sep 5;9(9):e106571. PMID: 25192188.
Lieber J, Ellerkamp V, Vogt F, et al. BH3-mimetic drugs prevent tumour onset in an orthotopic mouse model of hepatoblastoma. Exp Cell Res. 2014 Mar 10;322(1):217-25. PMID: 24355809.
